Nasdaq 100 Stocks SEC Filings — October 14, 2026

Q3 2026 net sales €11.7B and net income €5.0B, with FY2026 net sales guidance of €44-45B and ~56% gross margin; no prior-period comparison available in filing

CFO Agrawal sold 15,388 shares at $79.95 (~$1.23M) plus 7,191 at $80.51 (~$579K), leaving 110,017 shares; CRO Jones sold ~31,000 shares (~$2.4M) across two transactions, leaving 5,392 shares, both under 10b5-1 plans

CFO Amy Hood sold ~7,300 shares across three transactions at $544.80-$546.51 (~$2.99M total), retaining 555,396 shares under a 10b5-1 plan; the size relative to her holding is modest

COO Javier Olivan sold ~1,085 Class A shares across five transactions at $728.10 (~$790K total), retaining 76,213 shares under a 10b5-1 plan

EVP William Wilcox sold 1,100 shares at $958.21 (~$1.05M), retaining 3,094 shares; this is a small share of his holding and executed under a standard disclosure, not a plan-based sale

Director Eric Woersching sold 1,000 Class A shares at $205.00 (~$205K), retaining 3,465 shares; a small director sale with limited signal value

Board declared a quarterly dividend of $1.47 per share (record date Oct 30, payable Nov 13, 2026), a consistent capital return with no change disclosed

Company is a foreign private issuer whose summary financial statements are furnished via Exhibit 99.3, offering a disclosure path that can be checked against the full Q3 release

Two executives (CFO and CRO) sold a combined ~$3.8M in a single filing day at ~$77-$81, representing concentrated selling in the same name; both states of 10b5-1 plan execution reduce but do not eliminate the signal

Five of nine filings are insider sales across five different companies on the same day, all executed under 10b5-1 plans, which may reflect scheduled diversification rather than views on near-term prospects

COO Olivan's sales totaled ~$790K across five transactions, all at the identical $728.10 price, which suggests a single limit-order program executing through a 10b5-1 plan

Filing provides no period-over-period comparison and its financial statements are incorporated by reference to an exhibit not included in the source text, so growth and margin trends cannot be verified

DEFA14A excerpt contains only forward-looking statement disclaimers with no proposals, governance changes, or financial data, so the nature of the solicitation cannot be assessed

EVP Wilcox's 1,100-share sale (~$1.05M) occurred in a stock trading near $958, and the filing does not indicate a 10b5-1 plan, raising a question of discretionary timing

Full-year net sales guidance of €44-45B against Q3 net sales of €11.7B implies a strong Q4 run-rate if the range holds; the 56% gross margin guide is a key metric to monitor for upside

Routine $1.47 quarterly dividend with defined record and payment dates (Oct 30 / Nov 13) supports income-oriented positioning in a large-cap retailer

Exhibit 99.3 summary US GAAP statements are the next verification point for margin and EPS trends that the 6-K text itself omits

CFO Hood retains ~555,000 shares after sales, a large residual stake that signals continued alignment despite routine 10b5-1 selling

Insider sales at CoreWeave (two executives, ~$3.8M), Palantir (director, ~$205K), Microsoft (CFO, ~$3.0M), and Meta (COO, ~$790K) reflect routine, plan-driven diversification across high-valuation technology names; the aggregate is modest relative to these companies' market capitalizations but is consistent across the cohort, which may matter for sentiment if sales persist

Most insider transactions in this filing batch (Microsoft, Meta, CoreWeave, Palantir) were executed under 10b5-1 plans, which reduces the informational content of individual sales but means the aggregate schedule is pre-set and predictable

ASML's FY2026 guidance of €44-45B is the only quantified operating outlook in the batch and anchors the semiconductor capital-equipment cycle, which is relevant to AI-infrastructure names such as CoreWeave

Monitor whether Q4 net sales track toward the €44-45B full-year guidance, and whether the ~56% gross margin holds; next earnings date not stated in the filing

Track whether the CFO and CRO sales continue under the same 10b5-1 plans; additional Form 4 filings would confirm a sustained selling program

Watch whether the three-transaction sale recurs on a regular schedule; retained holding of ~555,000 shares is large

Monitor for further Form 4 filings to confirm whether the $728.10 limit-price sales continue

Routine payment date; confirm payment and watch for any change in the dividend rate at the next declaration

Supplemental proxy material filed Oct 14, 2026 without substantive content in the excerpt; review the full proxy for shareholder proposals before the meeting date